Mission 2030: Toward universal hepatitis B immunization.

Area of Science:

• Hepatitis B Virus (HBV) research
• Vaccinology
• Public Health

Background:

• Hepatitis B virus (HBV) infections remain a significant global health concern, leading to chronic hepatitis, liver cirrhosis, and cancer.
• Despite over 40 years of available vaccines, high infection rates persist, particularly in large populations.
• The World Health Organization (WHO) targets a 90% reduction in HBV cases by 2030 through its Immunization Agenda 2030.

Purpose of the Study:

• To review the challenges associated with current hepatitis B vaccination strategies.
• To explore novel vaccine technologies and administration routes for improved efficacy and coverage.
• To highlight the need for policy changes to achieve universal hepatitis B immunization.

Main Methods:

• Review of existing hepatitis B vaccines and immunization protocols.
• Analysis of challenges including multi-dose regimens and reduced adult efficacy.
• Evaluation of promising novel vaccine candidates with enhanced adjuvants, alternative antigens, and innovative delivery.

Main Results:

• Legacy vaccines, while important, face limitations in regimen convenience and adult efficacy.
• Novel vaccines demonstrate potential to overcome current hurdles through improved formulations and administration.
• Development of two-dose vaccines for children and policy implementation are crucial for increased vaccine coverage.

Conclusions:

• Achieving global hepatitis B control requires addressing limitations of current vaccines.
• Innovative vaccine approaches are essential for improving efficacy, coverage, and convenience.
• Policy endorsement and implementation of new vaccination strategies are vital for attaining the WHO's 2030 goals.